Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Use of von Willebrand Factor Concentrate in Inherited von Willebrand Disease: How Often Is It Useful to Add Factor VIII?

Drillaud N, Ardillon L, Ternisien C, Valentin JB, Fouassier M, Gillet B, Gruel Y, Sigaud M, Horvais V, Bene MC, Trossaërt M.

Transfus Med Rev. 2019 Nov 1. pii: S0887-7963(19)30139-7. doi: 10.1016/j.tmrv.2019.10.004. [Epub ahead of print] No abstract available.

PMID:
31813707
2.

Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra® ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP).

Susen S, Gruel Y, Godier A, Harroche A, Chambost H, Lasne D, Rauch A, Roullet S, Fontana P, Goudemand J, de Maistre E, Chamouard V, Wibaut B, Albaladejo P, Négrier C.

Haemophilia. 2019 Sep;25(5):731-737. doi: 10.1111/hae.13817. Epub 2019 Jul 11. Review.

PMID:
31294904
3.

Frequency and Clinical Impact of Platelet Factor 4-Specific Antibodies in Patients Undergoing Extracorporeal Membrane Oxygenation.

Vayne C, May MA, Bourguignon T, Lemoine E, Guery EA, Rollin J, Gruel Y, Pouplard C.

Thromb Haemost. 2019 Jul;119(7):1138-1146. doi: 10.1055/s-0039-1688827. Epub 2019 May 26.

PMID:
31129914
4.

Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.

Kizlik-Masson C, Deveuve Q, Zhou Y, Vayne C, Thibault G, McKenzie SE, Pouplard C, Loyau S, Gruel Y, Rollin J.

Blood. 2019 May 30;133(22):2427-2435. doi: 10.1182/blood.2019000437. Epub 2019 Mar 27.

PMID:
30917957
5.

Fibronectin: a "double hit" modulator in HIT?

Gruel Y, Rollin J.

Blood. 2019 Feb 28;133(9):891-892. doi: 10.1182/blood-2019-01-894295. No abstract available.

PMID:
30819779
6.

Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR).

Godier A, Garrigue D, Lasne D, Fontana P, Bonhomme F, Collet JP, de Maistre E, Ickx B, Gruel Y, Mazighi M, Nguyen P, Vincentelli A, Albaladejo P, Lecompte T; French Working Group on Perioperative Haemostasis (GIHP).

Arch Cardiovasc Dis. 2019 Mar;112(3):199-216. doi: 10.1016/j.acvd.2018.10.004. Epub 2019 Jan 6.

PMID:
30621917
7.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N.

Blood Adv. 2018 Nov 27;2(22):3360-3392. doi: 10.1182/bloodadvances.2018024489.

8.

Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR).

Godier A, Garrigue D, Lasne D, Fontana P, Bonhomme F, Collet JP, de Maistre E, Ickx B, Gruel Y, Mazighi M, Nguyen P, Vincentelli A, Albaladejo P, Lecompte T.

Anaesth Crit Care Pain Med. 2019 Jun;38(3):289-302. doi: 10.1016/j.accpm.2018.10.004. Epub 2018 Oct 23.

9.

[Risk factors for thromboembolic disease in young women-the role of hormones].

Tromeur C, Le Mao R, Jego P, El-Kouri D, Gruel Y, Pan-Petesch B, Bertoletti L, Morange PE, Lemoigne E, Paleiron N, Leroyer C, Couturaud F.

Rev Mal Respir. 2019 Feb;36(2):219-226. doi: 10.1016/j.rmr.2018.05.013. Epub 2018 Oct 11. French.

PMID:
30318429
10.

Determinants of adherence and consequences of the transition from adolescence to adulthood among young people with severe haemophilia (TRANSHEMO): study protocol for a multicentric French national observational cross-sectional study.

Resseguier N, Rosso-Delsemme N, Beltran Anzola A, Baumstarck K, Milien V, Ardillon L, Bayart S, Berger C, Bertrand MA, Biron-Andreani C, Borel-Derlon A, Castet S, Chamouni P, Claeyssens Donadel S, De Raucourt E, Desprez D, Falaise C, Frotscher B, Gay V, Goudemand J, Gruel Y, Guillet B, Harroche A, Hassoun A, Huguenin Y, Lambert T, Lebreton A, Lienhart A, Martin M, Meunier S, Monpoux F, Mourey G, Negrier C, Nguyen P, Nyombe P, Oudot C, Pan-Petesch B, Polack B, Rafowicz A, Rauch A, Rivaud D, Schneider P, Spiegel A, Stoven C, Tardy B, Trossaërt M, Valentin JB, Vanderbecken S, Volot F, Voyer-Ebrard A, Wibaut B, Leroy T, Sannie T, Chambost H, Auquier P.

BMJ Open. 2018 Jul 25;8(7):e022409. doi: 10.1136/bmjopen-2018-022409.

11.

Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.

Maruani A, Boccara O, Bessis D, Guibaud L, Vabres P, Mazereeuw-Hautier J, Barbarot S, Chiaverini C, Blaise S, Droitcourt C, Mallet S, Martin L, Lorette G, Woillard JB, Jonville-Bera AP, Rollin J, Gruel Y, Herbreteau D, Goga D, le Touze A, Leducq S, Gissot V, Morel B, Tavernier E, Giraudeau B; Groupe de Recherche de la Societé Française de Dermatologie Pédiatrique.

Trials. 2018 Jun 27;19(1):340. doi: 10.1186/s13063-018-2725-1.

12.

Analysis of big data for heparin-induced thrombocytopenia: valuable information but also some doubts.

Gruel Y.

Lancet Haematol. 2018 May;5(5):e188-e189. doi: 10.1016/S2352-3026(18)30050-4. No abstract available.

PMID:
29703334
13.

Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms.

Narata AP, Amelot A, Bibi R, Herbreteau D, Angoulvant D, Gruel Y, Janot K.

Neurosurgery. 2019 Jan 1;84(1):77-83. doi: 10.1093/neuros/nyy002.

PMID:
29490066
14.

Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR).

Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; French Working Group on perioperative hemostasis (GIHP).

Arch Cardiovasc Dis. 2018 Mar;111(3):210-223. doi: 10.1016/j.acvd.2017.12.004. Epub 2018 Feb 3. Review. No abstract available.

15.

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants.

Touzé E, Gruel Y, Gouin-Thibault I, De Maistre E, Susen S, Sie P, Derex L.

Eur J Neurol. 2018 May;25(5):747-e52. doi: 10.1111/ene.13582. Epub 2018 Mar 9.

PMID:
29360254
16.

Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR).

Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; members of the French Working Group on perioperative haemostasis (GIHP).

Anaesth Crit Care Pain Med. 2018 Aug;37(4):379-389. doi: 10.1016/j.accpm.2017.12.012. Epub 2018 Jan 5. Review.

17.

Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.

Négrier C, Ducloy-Bouthors AS, Piriou V, De Maistre E, Stieltjes N, Borel-Derlon A, Colson P, Picard J, Lambert T, Claeyssens S, Boileau S, Bertrand A, André MH, Fourrier F, Ozier Y, Sié P, Gruel Y, Tellier Z.

Vox Sang. 2018 Feb;113(2):120-127. doi: 10.1111/vox.12624. Epub 2017 Dec 13.

PMID:
29238971
18.

Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies.

Vayne C, Guery EA, Kizlik-Masson C, Rollin J, Bauters A, Gruel Y, Pouplard C.

Br J Haematol. 2017 Dec;179(5):811-819. doi: 10.1111/bjh.14955. Epub 2017 Oct 19.

PMID:
29048130
19.

Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J; for FranceCoag Collaborators.

Haematologica. 2018 Jan;103(1):179-189. doi: 10.3324/haematol.2017.174706. Epub 2017 Oct 12.

20.

Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.

Gouin-Thibault I, Freyburger G, de Maistre E, Susen S, Delavenne X, Golmard JL, Gruel Y, Sié P; GFHT study group on DOAC.

Thromb Res. 2017 Oct;158:126-133. doi: 10.1016/j.thromres.2017.09.001. Epub 2017 Sep 4.

PMID:
28892657
21.

[Neonatal arterial ischemic stroke: Which thrombotic biological risk factors to investigate and which practical consequences?]

Perez T, Valentin JB, Saliba E, Gruel Y.

Arch Pediatr. 2017 Sep;24(9S):9S28-9S34. doi: 10.1016/S0929-693X(17)30328-7. Review. French.

PMID:
28867034
22.

Immunogenicity, efficacy and safety of Nuwiq® (human-cl rhFVIII) in previously untreated patients with severe haemophilia A-Interim results from the NuProtect Study.

Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Guillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ.

Haemophilia. 2018 Mar;24(2):211-220. doi: 10.1111/hae.13320. Epub 2017 Aug 16.

PMID:
28815880
23.

5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies.

Kizlik-Masson C, Vayne C, McKenzie SE, Poupon A, Zhou Y, Champier G, Pouplard C, Gruel Y, Rollin J.

J Thromb Haemost. 2017 Oct;15(10):2065-2075. doi: 10.1111/jth.13786. Epub 2017 Sep 4.

24.

Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants: An Observational Registry Analysis.

Albaladejo P, Samama CM, Sié P, Kauffmann S, Mémier V, Suchon P, Viallon A, David JS, Gruel Y, Bellamy L, de Maistre E, Romegoux P, Thoret S, Pernod G, Bosson JL; GIHP-NACO Study Group.

Anesthesiology. 2017 Jul;127(1):111-120. doi: 10.1097/ALN.0000000000001631.

PMID:
28410272
25.

[Neonatal arterial ischemic stroke: Review of the current guidelines].

Saliba E, Debillon T; Recommandations accident vasculaire cérébral (AVC) néonatal, Auvin S, Baud O, Biran V, Chabernaud JL, Chabrier S, Cneude F, Cordier AG, Darmency-Stamboul V, Diependaele JF, Debillon T, Dinomais M, Durand C, Ego A, Favrais G, Gruel Y, Hertz-Pannier L, Husson B, Marret S, N'Guyen The Tich S, Perez T, Saliba E, Valentin JB, Vuillerot C.

Arch Pediatr. 2017 Feb;24(2):180-188. doi: 10.1016/j.arcped.2016.11.005. Epub 2016 Dec 20. French.

PMID:
28011082
26.

The Taipan snake venom time can be used to detect lupus anticoagulant in patients treated by rivaroxaban.

Pouplard C, Vayne C, Berthomet C, Guery EA, Delahousse B, Gruel Y.

Int J Lab Hematol. 2017 Jun;39(3):e60-e63. doi: 10.1111/ijlh.12611. Epub 2016 Dec 22. No abstract available.

PMID:
28004514
27.

Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors.

Rollin J, Pouplard C, Gruel Y.

Thromb Haemost. 2016 Oct 28;116(5):799-805. Epub 2016 Jun 30. Review.

PMID:
27358188
28.

Post-authorization safety study of Clottafact® , a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study.

Négrier C, Rothschild C, Borg JY, Lambert T, Claeyssens S, Sanhes L, Stieltjes N, Bertrand A, André MH, Sié P, Gruel Y, Tellier Z.

Vox Sang. 2016 Nov;111(4):383-390. doi: 10.1111/vox.12424. Epub 2016 Sep 1.

PMID:
27583698
29.

No impact of PTPN22, PTPRJ and ACP1 genes polymorphisms on the risk of immune thrombocytopenia in French adult patients.

Lioger B, Rollin J, Vayne C, Perret-Gallix K, Pouplard C, Godeau B, Michel M, Gruel Y.

Thromb Res. 2016 Aug;144:76-8. doi: 10.1016/j.thromres.2016.04.013. Epub 2016 Apr 25. No abstract available.

PMID:
27309885
30.

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.

Rollin J, Payancé A, Gouilleux-Gruart V, Boisdron-Celle M, Azzopardi N, Morel A, Gruel Y, Paintaud G, Gamelin E, Watier H, Lecomte T.

Pharmacogenomics. 2015 Dec;16(18):2035-43. doi: 10.2217/pgs.15.139. Epub 2015 Nov 30.

PMID:
26615857
31.

Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial.

Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andréani C, Gruel Y, Morel J, Wynckel A, Grunebaum L, Villacorta-Torres J, Grosjean S, de Maistre E.

Crit Care. 2015 Nov 11;19:396. doi: 10.1186/s13054-015-1109-0.

32.

A rapid test (STic Expert® ) for the diagnosis of heparin-induced thrombocytopenia--response to De Cooman and Devreese.

Pouplard C, Gruel Y.

Br J Haematol. 2016 Feb;172(3):466-7. doi: 10.1111/bjh.13490. Epub 2015 May 11. No abstract available.

PMID:
25959988
33.

Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.

Nurden AT, Pillois X, Fiore M, Alessi MC, Bonduel M, Dreyfus M, Goudemand J, Gruel Y, Benabdallah-Guerida S, Latger-Cannard V, Négrier C, Nugent D, Oiron RD, Rand ML, Sié P, Trossaert M, Alberio L, Martins N, Sirvain-Trukniewicz P, Couloux A, Canault M, Fronthroth JP, Fretigny M, Nurden P, Heilig R, Vinciguerra C.

Hum Mutat. 2015 May;36(5):548-61. doi: 10.1002/humu.22776.

34.

Increased risk of thrombosis in FcγRIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2.

Rollin J, Pouplard C, Sung HC, Leroux D, Saada A, Gouilleux-Gruart V, Thibault G, Gruel Y.

Blood. 2015 Apr 9;125(15):2397-404. doi: 10.1182/blood-2014-09-594515. Epub 2015 Feb 13.

PMID:
25680756
35.

Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.

Lapalud P, Rothschild C, Mathieu-Dupas E, Balicchi J, Gruel Y, Laune D, Molina F, Schved JF, Granier C, Lavigne-Lissalde G.

J Thromb Haemost. 2015 Apr;13(4):540-7. doi: 10.1111/jth.12846. Epub 2015 Feb 27.

36.

A genome-wide association study of heparin-induced thrombocytopenia using an electronic medical record.

Karnes JH, Cronin RM, Rollin J, Teumer A, Pouplard C, Shaffer CM, Blanquicett C, Bowton EA, Cowan JD, Mosley JD, Van Driest SL, Weeke PE, Wells QS, Bakchoul T, Denny JC, Greinacher A, Gruel Y, Roden DM.

Thromb Haemost. 2015 Apr;113(4):772-81. doi: 10.1160/TH14-08-0670. Epub 2014 Dec 11.

37.

Prospective evaluation of a rapid nanoparticle-based lateral flow immunoassay (STic Expert(®) HIT) for the diagnosis of heparin-induced thrombocytopenia.

Leroux D, Hezard N, Lebreton A, Bauters A, Suchon P, de Maistre E, Biron C, Huisse MG, Ternisien C, Voisin S, Gruel Y, Pouplard C.

Br J Haematol. 2014 Sep;166(5):774-82. doi: 10.1111/bjh.12939. Epub 2014 May 12.

PMID:
24815503
38.

Venous thromboembolism prophylaxis in patients undergoing abdominal or pelvic surgery for cancer--a real-world, prospective, observational French study: PRéOBS.

Samama CM, Boubli L, Coloby P, Debourdeau P, Gruel Y, Mariette C, Mottier D, Rischmann P, Toubiana L, Steib A.

Thromb Res. 2014 Jun;133(6):985-92. doi: 10.1016/j.thromres.2013.10.038. Epub 2013 Nov 1.

PMID:
24231117
39.

[Heparin-induced thrombocytopenia: recent data].

Gruel Y, Rollin J, Leroux D, Pouplard C.

Rev Med Interne. 2014 Mar;35(3):174-82. doi: 10.1016/j.revmed.2013.04.022. Epub 2013 Sep 26. Review. French.

PMID:
24074968
40.

[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P.

Ann Fr Anesth Reanim. 2013 Oct;32(10):691-700. doi: 10.1016/j.annfar.2013.04.016. Epub 2013 Aug 30. Review. French. Erratum in: Ann Fr Anesth Reanim. 2014 Mar;33(3):198-9.

PMID:
23993157
41.

Letter by May et al regarding article, "Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.

May MA, Gruel Y, Fauchier L.

Circ Arrhythm Electrophysiol. 2013 Aug;6(4):e65. doi: 10.1161/CIRCEP.113.000515. Epub 2013 Jul 30. No abstract available.

PMID:
23899712
42.

Cerebral venous thrombosis in an elderly adult treated with diethylstilbestrol.

Ponce E, Cottier JP, Gruel Y, Hommet C, Mondon K.

J Am Geriatr Soc. 2013 Jul;61(7):1242-3. doi: 10.1111/jgs.12337. No abstract available.

PMID:
23855866
43.

Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.

Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis.

Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.

44.

Incidence of antibodies to protamine sulfate/heparin complexes incardiac surgery patients and impact on platelet activation and clinical outcome.

Pouplard C, Leroux D, Rollin J, Amiral J, May MA, Gruel Y.

Thromb Haemost. 2013 Jun;109(6):1141-7. doi: 10.1160/TH12-11-0844. Epub 2013 May 2.

PMID:
23636177
45.

Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4-heparin complexes.

Rollin J, Pouplard C, Leroux D, May MA, Gruel Y.

J Thromb Haemost. 2013 Aug;11(8):1609-11. doi: 10.1111/jth.12278. No abstract available.

46.

Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.

Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.

Haemophilia. 2013 Mar;19(2):281-6. doi: 10.1111/hae.12018. Epub 2012 Oct 8.

PMID:
23038998
47.

Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis.

Warkentin TE, Greinacher A, Gruel Y, Aster RH, Chong BH; scientific and standardization committee of the international society on thrombosis and haemostasis.

J Thromb Haemost. 2011 Dec;9(12):2498-500. doi: 10.1111/j.1538-7836.2011.04536.x. No abstract available.

48.

The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.

Lapalud P, Ali T, Cayzac C, Mathieu-Dupas E, Levesque H, Pfeiffer C, Balicchi J, Gruel Y, Borg JY, Schved JF, Granier C, Lavigne-Lissalde G.

J Thromb Haemost. 2012 Sep;10(9):1814-22. doi: 10.1111/j.1538-7836.2012.04850.x.

49.

Polymorphisms of protein tyrosine phosphatase CD148 influence FcγRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia.

Rollin J, Pouplard C, Gratacap MP, Leroux D, May MA, Aupart M, Gouilleux-Gruart V, Payrastre B, Gruel Y.

Blood. 2012 Aug 9;120(6):1309-16. doi: 10.1182/blood-2012-04-424044. Epub 2012 Jun 7.

PMID:
22677127
50.

Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia.

Pouplard C, Cornillet-Lefebvre P, Attaoua R, Leroux D, Lecocq-Lafon C, Rollin J, Grigorescu F, Nguyen P, Gruel Y.

Thromb Res. 2012 Apr;129(4):465-9. doi: 10.1016/j.thromres.2011.09.033. Epub 2012 Jan 10.

PMID:
22239992

Supplemental Content

Support Center